Lycorine suppresses RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chen, Shuai ^a,b   Jin, Gu ^a,d   Huang, Kang Mao ^a,b   Ma, Jian Jun ^a,b   Wang, Qiang ^a,b   Ma, Yan ^a,b   Tang, Xiao Zhen ^a,b   Zhou, Zhi Jie ^a,b   Hu, Zhi Jun ^a,b   Wang, Ji Ying ^b   Qin, An ^c   Fan, Shun Wu ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b Key Laboratory of Biotherapy of Zhejiang Province   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMARYLLIDACEAE ALKALOID; BONE DENSITY CONSERVATION AGENT; LYCORINE; MAP2K7 PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; OSTEOCLAST DIFFERENTIATION FACTOR; PHENANTHRIDINE DERIVATIVE; TITANIUM; TNFSF11 PROTEIN, MOUSE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BONE DEVELOPMENT; BONE MARROW; C57BL MOUSE; CELL DIFFERENTIATION; CELL SURVIVAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MACROPHAGE; MALE; METABOLISM; MOUSE; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PATHOLOGY; PREVENTION AND CONTROL; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

AMARYLLIDACEAE ALKALOIDS; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE MARROW; CELL DIFFERENTIATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; MACROPHAGES; MALE; MAP KINASE KINASE 4; MAP KINASE KINASE 7; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OSTEOCLASTS; OSTEOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PHENANTHRIDINES; PRIMARY CELL CULTURE; RANK LIGAND; SIGNAL TRANSDUCTION; TITANIUM;

EID: 84938630312     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12853     Document Type: Article

References (44)

1. Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337-342 (2003).
2. Teitelbaum, S. L. & Ross, F. P. Genetic regulation of osteoclast development and function. Nat Rev Genet 4, 638-649 (2003).
3. Takahashi, N., Udagawa, N., Tanaka, S. & Suda, T. Generating murine osteoclasts from bone marrow. Methods Mol Med 80, 129-144 (2003).
4. Darnay, B. G., Ni, J., Moore, P. A. & Aggarwal, B. B. Activation of NF-kappaB by RANK requires tumor necrosis factor receptorassociated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 274, 7724-7731 (1999).
5. Takaesu, G. et al. Interleukin-1 (IL-1) receptor-associated kinase leads to activation of TAK1 by inducing TAB2 translocation in the IL-1 signaling pathway. Mol Cell Biol 21, 2475-2484 (2001).
6. Pearson, G. et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22, 153-183 (2001).
7. Monje, P., Hernandez-Losa, J., Lyons, R. J., Castellone, M. D. & Gutkind, J. S. Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1. J Biol Chem 280, 35081-35084 (2005).
8. Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3, 889-901 (2002).
9. Rizzoli, R., Yasothan, U. & Kirkpatrick, P. Denosumab. Nature Reviews. Drug Discovery 9, 591-592 (2010).
10. Whelan, A. M., Jurgens, T. M. & Bowles, S. K. Natural health products in the prevention and treatment of osteoporosis: systematic review of randomized controlled trials. Ann Pharmacother 40, 836-849 (2006).
11. Kumar, M. et al. Anti-osteoporotic constituents from Indian medicinal plants. Phytomedicine 17, 993-999 (2010).
12. Wong, R. W. & Rabie, A. B. Traditional Chinese medicines and bone formation - a review. J Oral Maxillofac Surg 64, 828-837 (2006).
13. Putnam, S. E., Scutt, A. M., Bicknell, K., Priestley, C. M. & Williamson, E. M. Natural products as alternative treatments for metabolic bone disorders and for maintenance of bone health. Phytother Res 21, 99-112 (2007).
14. Ouyang, Z. et al. Hypericin suppresses osteoclast formation and wear particle-induced osteolysis via modulating ERK signalling pathway. Biochemical Pharmacology 90, 276-287 (2014).
15. Qu, X. et al. Dioscin inhibits osteoclast differentiation and bone resorption though down-regulating the Akt signaling cascades. Biochemical and Biophysical Research Communications 443, 658-665 (2014).
16. Zhai, Z. et al. Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling. Breast Cancer Research and Treatment 144, 33-45 (2014).
17. Zupko, I. et al. Antitumor activity of alkaloids derived from Amaryllidaceae species. In Vivo 23, 41-48 (2009).
18. Citoglu, G. S., Acikara, O. B., Yilmaz, B. S. & Ozbek, H. Evaluation of analgesic, anti-inflammatory and hepatoprotective effects of lycorine from Sternbergia fisheriana (Herbert) Rupr. Fitoterapia 83, 81-87 (2012).
19. Liu, J. et al. Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication. Virol J 8, 483 (2011).
20. Toriizuka, Y. et al. New lycorine-type alkaloid from Lycoris traubii and evaluation of antitrypanosomal and antimalarial activities of lycorine derivatives. Bioorg Med Chem 16, 10182-10189 (2008).
21. Cao, Z. et al. Lycorine hydrochloride selectively inhibits human ovarian cancer cell proliferation and tumor neovascularization with very low toxicity. Toxicol Lett 218, 174-185 (2013).
22. Li, L. et al. Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition. Cancer Cell Int 12, 49 (2012).
23. Liu, R. et al. Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry. Pigment Cell Melanoma Res 25, 630-638 (2012).
24. Kang, J. et al. Lycorine inhibits lipopolysaccharide-induced iNOS and COX-2 up-regulation in RAW264.7 cells through suppressing P38 and STATs activation and increases the survival rate of mice after LPS challenge. Int Immunopharmacol 12, 249-256 (2012).
25. Schett, G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res Ther 9, 203 (2007).
26. Teitelbaum, S. L. Bone Resorption by Osteoclasts. Science 289, 1504-1508 (2000).
27. Zhai, Z. J. et al. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. Br J Pharmacol 171, 663-675 (2014).
28. Miyazaki, T., Tokimura, F. & Tanaka, S. A review of denosumab for the treatment of osteoporosis. Patient Prefer Adherence 8, 463-471 (2014).
29. Delmas, P. D. et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337, 1641-1647 (1997).
30. McClung, M. R. et al. Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. J Clin Endocrinol Metab 89, 4879-4885 (2004).
31. Delmas, P. D. Treatment of postmenopausal osteoporosis. Lancet 359, 2018-2026 (2002).
32. Colditz, G. A. Hormone replacement therapy increases the risk of breast cancer. Ann N Y Acad Sci 833, 129-136 (1997).
33. Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002).
34. Verron, E. & Bouler, J. M. Is bisphosphonate therapy compromised by the emergence of adverse bone disorders? Drug Discov Today 19, 312-319 (2014).
35. Hiligsmann, M., Boonen, A., Dirksen, C. D., Ben Sedrine, W. & Reginster, J. Y. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women. Expert Rev Pharmacoecon Outcomes Res 13, 19-28 (2013).
36. Darling, N. J. & Cook, S. J. The role of MAPK signalling pathways in the response to endoplasmic reticulum stress. Biochim Biophys Acta 1843, 2150-2163 (2014).
37. Ouyang, Z. et al. Hypericin suppresses osteoclast formation and wear particle-induced osteolysis via modulating ERK signalling pathway. Biochem Pharmacol 90, 276-287 (2014).
38. Matsumoto, M., Sudo, T., Saito, T., Osada, H. & Tsujimoto, M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 275, 31155-31161 (2000).
39. David, J. P., Sabapathy, K., Hoffmann, O., Idarraga, M. H. & Wagner, E. F. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci 115, 4317-4325 (2002).
40. Lu, Y. C., Yeh, W. C. & Ohashi, P. S. LPS/TLR4 signal transduction pathway. Cytokine 42, 145-151 (2008).
41. Matsumoto, M. et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 279, 45969-45979 (2004).
42. Kim, Y. et al. Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclastassociated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis. J Biol Chem 280, 32905-32913 (2005).
43. Qin, A. et al. Prevention of wear particle-induced osteolysis by a novel V-ATPase inhibitor saliphenylhalamide through inhibition of osteoclast bone resorption. PLoS One 7, e34132 (2012).
44. Chen, S. et al. Upregulation of tumor necrosis factor alpha and ADAMTS-5, but not ADAMTS-4, in human intervertebral cartilage endplate with modic changes. Spine (Phila Pa 1976) 39, E817-825 (2014).